Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease
- Conditions
- Polycystic Kidney, Autosomal DominantChronic Kidney Disease
- Registration Number
- NCT01114594
- Lead Sponsor
- The Rogosin Institute
- Brief Summary
The aim of this pilot project is to assess the potential of urine micro-RNAs (miRNA) as biomarkers for characterizing patients with autosomal dominant polycystic kidney disease (ADPKD) compared with patients with other causes of chronic kidney disease.
- Detailed Description
Proteins and small molecules in urine (biomarkers) have been used to probe for kidney and systemic diseases for hundreds of years. Urine reportedly contains a type of molecule called microRNA (miRNAs) that regulate a large number of biological processes. Impaired function of miRNAs is now recognized in an increasing number of disease processes. In the search for new biomarkers, the regulatory function of miRNAs and the relative simplicity and precision of characterizing miRNAs, are potential advantages when compared to traditional biomarkers.
The aim of this pilot project is to assess the potential of urine miRNAs as biomarkers for characterizing patients with autosomal dominant polycystic kidney disease (ADPKD), the most prevalent inherited cause of kidney failure. Individuals with other causes of chronic kidney disease (e.g., diabetes, glomerulonephritis), who are matched for key characteristics (e.g. age, sex, level of kidney function) will serve as the control population. A technique for isolation of miRNAs from urine samples will be tailored for the specific needs of this project. Biochemical and computational analysis of small RNAs from these samples will provide urine miRNA profiles and key variability statistics that will be use to design follow-up projects involving patients with kidney disease.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 42
- Male or female subject, 18 years of age or older, with diagnosis of ADPKD or non-PKD-CKD
- If female, not pregnant.
- Willing and able to understand and sign informed consent
- Presenting with any signs or symptoms of an infectious disease
- Bacterial infection determined by urine culture
- Use of systemic steroids within a week prior to screening
- History, physical, or laboratory findings suggestive of any other medical or psychological condition that would, in the opinion of the Principal Investigator, make the candidate ineligible for the study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of micro-RNA Biomarkers Associated with Autosomal Dominant Chronic Kidney Disease 5 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The Rogosin Institute
🇺🇸New York, New York, United States